Xenon Pharmaceuticals Inc. (XENE) 14.25 $XENE
Xenon Pharmaceuticals Is Set To Takeoff In 2015
EST Invest - at Seeking Alpha - Thu Apr 09, 3:56PM CDT
XENE: 14.25 (-0.66)
Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 8:40AM CDT
Teva (TEVA) and Xenon Pharmaceuticals (XENE) announced the enrolment of the first patient in a phase IIb study on TV-45070, being developed for the treatment of patients suffering from postherpetic neuralgia.
XENE: 14.25 (-0.66), AKRX: 53.70 (-1.69), TEVA: 63.01 (-1.15), ACOR: 33.34 (-1.33)
Teva and Xenon report first patient enrolled in Phase 2 PHN study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 9:09AM CDT
XENE: 14.25 (-0.66), TEVA: 63.01 (-1.15)
Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
GlobeNewswire - Thu Apr 02, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the first patient has been enrolled into the Phase 2b study designed to evaluate the safety and efficacy of the novel topically applied TV-45070, (4% and 8% w/w Ointment) in patients with Postherpetic Neuralgia (PHN).
XENE: 14.25 (-0.66), TEVA: 63.01 (-1.15)
Xenon Pharmaceuticals elects Dr Richard H. Scheller to board
M2 - Tue Mar 17, 3:25AM CDT
Biopharmaceutical company Xenon Pharmaceuticals (NasdaqGM:XENE) reported on Monday the addition of Richard H. Scheller, PhD to its board of directors.
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors
GlobeNewswire - Mon Mar 16, 7:00AM CDT
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Richard H. Scheller, Ph.D., has been appointed to its Board of Directors. Dr. Scheller is a globally recognized leader in biomedical research, and the former Executive Vice President of Research and Early Development at Genentech, where he was responsible for setting the strategy for Genentech's research and drug discovery activities, and was involved in the successful development and approval of important biotechnology products. Dr. Scheller was recently appointed as Chief Science Officer and Head of Therapeutics at 23andMe.
XENE: 14.25 (-0.66)
Xenon Pharma reports FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:39PM CDT
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 12, 3:00PM CDT
Progress in Partnered Programs and Proprietary Development Pipeline
QURE: 26.15 (-1.44), XENE: 14.25 (-0.66), ROG: 80.18 (+2.56), TEVA: 63.01 (-1.15)
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
GlobeNewswire - Mon Mar 09, 7:30AM CDT
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2014 financial and operating results after the close of U.S. financial markets on Thursday, March 12, 2015. Xenon management will host a conference call and live audio webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) the same day to discuss those results and to provide a corporate update.
XENE: 14.25 (-0.66)
15 Biggest Buys Buffett, Icahn and Other Big Investors Made Last Quarter
at The Street - Mon Feb 23, 7:08AM CST
Heavy-hitting investors like Warren Buffett, George Soros and David Einhorn actively bought new stock positions last quarter. See which stocks they bought.
ZTS: 47.03 (-0.51), LYB: 97.11 (+0.56), HTZ: 21.38 (+0.31), IBM: 165.36 (+1.10), XENE: 14.25 (-0.66), AMGN: 169.10 (+0.64), ARCP: 9.27 (+0.08), TRCO: 56.14 (+0.98), AAPL: 128.62 (+1.71), PCLN: 1,212.90 (+18.64), TWX: 84.46 (+0.42), SRSC: 7.81 (-0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 11:46AM CST
UIHC: 20.78 (+0.18), TILE: 21.12 (+0.21), MELA: 1.52 (-0.14), IPAS: 1.21 (-0.02), HSTM: 29.05 (-0.15), ASTI: 1.07 (+0.04), CSLT: 7.85 (+0.36), GTS: 19.36 (-0.01), I: 11.87 (-0.08), ADPT: 52.15 (-2.38), BCC: 38.42 (-0.13), SMLR: 3.25 (+0.08), AXDX: 23.62 (+0.10), CLRX: 0.95 (unch), XTLB: 2.30 (unch), XENE: 14.25 (-0.66), BJRI: 50.54 (-1.00), ATRO: 76.14 (+1.39), IKGH: 1.88 (-0.13), OGEN: 0.97 (+0.09)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), ANIK: 38.68 (+0.05), CBYL: 7.02 (-0.38)
Xenon off on profit taking
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 11:01AM CST
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals (XENE) Jumps: Stock Surges 16.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 8:11AM CST
Xenon Pharmaceuticals Inc. (XENE) was a big mover last session, as the company saw its shares rise by nearly 17% on the day.
ANIP: 69.79 (+1.24), XENE: 14.25 (-0.66)
Market News: Manitowoc, Xenon Pharmaceuticals, USMD Holdings
at The Street - Mon Dec 29, 3:43PM CST
The stock markets in the United States fluctuated and eventually ended the trading session higher except Dow Jones Industrial Average (DJIA), down by 0.9% today. Sign up for our free daily newsletter ...
XENE: 14.25 (-0.66), USMD: 10.37 (-0.08), MTW: 19.99 (+0.39)
Xenon Pharma continues up move
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 9:25AM CST
XENE: 14.25 (-0.66)
Xenon Pharma ups earnings 44% in Q3
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:43AM CST
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals Is Set To Takeoff In 2015
EST Invest - at Seeking Alpha - Thu Apr 09, 3:56PM CDT
XENE: 14.25 (-0.66)
Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 8:40AM CDT
Teva (TEVA) and Xenon Pharmaceuticals (XENE) announced the enrolment of the first patient in a phase IIb study on TV-45070, being developed for the treatment of patients suffering from postherpetic neuralgia.
XENE: 14.25 (-0.66), AKRX: 53.70 (-1.69), TEVA: 63.01 (-1.15), ACOR: 33.34 (-1.33)
Teva and Xenon report first patient enrolled in Phase 2 PHN study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 9:09AM CDT
XENE: 14.25 (-0.66), TEVA: 63.01 (-1.15)
Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
GlobeNewswire - Thu Apr 02, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the first patient has been enrolled into the Phase 2b study designed to evaluate the safety and efficacy of the novel topically applied TV-45070, (4% and 8% w/w Ointment) in patients with Postherpetic Neuralgia (PHN).
XENE: 14.25 (-0.66), TEVA: 63.01 (-1.15)
Xenon Pharmaceuticals elects Dr Richard H. Scheller to board
M2 - Tue Mar 17, 3:25AM CDT
Biopharmaceutical company Xenon Pharmaceuticals (NasdaqGM:XENE) reported on Monday the addition of Richard H. Scheller, PhD to its board of directors.
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors
GlobeNewswire - Mon Mar 16, 7:00AM CDT
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Richard H. Scheller, Ph.D., has been appointed to its Board of Directors. Dr. Scheller is a globally recognized leader in biomedical research, and the former Executive Vice President of Research and Early Development at Genentech, where he was responsible for setting the strategy for Genentech's research and drug discovery activities, and was involved in the successful development and approval of important biotechnology products. Dr. Scheller was recently appointed as Chief Science Officer and Head of Therapeutics at 23andMe.
XENE: 14.25 (-0.66)
Xenon Pharma reports FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:39PM CDT
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 12, 3:00PM CDT
Progress in Partnered Programs and Proprietary Development Pipeline
QURE: 26.15 (-1.44), XENE: 14.25 (-0.66), ROG: 80.18 (+2.56), TEVA: 63.01 (-1.15)
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
GlobeNewswire - Mon Mar 09, 7:30AM CDT
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2014 financial and operating results after the close of U.S. financial markets on Thursday, March 12, 2015. Xenon management will host a conference call and live audio webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) the same day to discuss those results and to provide a corporate update.
XENE: 14.25 (-0.66)
15 Biggest Buys Buffett, Icahn and Other Big Investors Made Last Quarter
at The Street - Mon Feb 23, 7:08AM CST
Heavy-hitting investors like Warren Buffett, George Soros and David Einhorn actively bought new stock positions last quarter. See which stocks they bought.
ZTS: 47.03 (-0.51), LYB: 97.11 (+0.56), HTZ: 21.38 (+0.31), IBM: 165.36 (+1.10), XENE: 14.25 (-0.66), AMGN: 169.10 (+0.64), ARCP: 9.27 (+0.08), TRCO: 56.14 (+0.98), AAPL: 128.62 (+1.71), PCLN: 1,212.90 (+18.64), TWX: 84.46 (+0.42), SRSC: 7.81 (-0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 11:46AM CST
UIHC: 20.78 (+0.18), TILE: 21.12 (+0.21), MELA: 1.52 (-0.14), IPAS: 1.21 (-0.02), HSTM: 29.05 (-0.15), ASTI: 1.07 (+0.04), CSLT: 7.85 (+0.36), GTS: 19.36 (-0.01), I: 11.87 (-0.08), ADPT: 52.15 (-2.38), BCC: 38.42 (-0.13), SMLR: 3.25 (+0.08), AXDX: 23.62 (+0.10), CLRX: 0.95 (unch), XTLB: 2.30 (unch), XENE: 14.25 (-0.66), BJRI: 50.54 (-1.00), ATRO: 76.14 (+1.39), IKGH: 1.88 (-0.13), OGEN: 0.97 (+0.09)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), CBYL: 7.02 (-0.38), ANIK: 38.68 (+0.05)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 122.95 (-2.22), FLXN: 18.77 (-0.78), XENE: 14.25 (-0.66), HZNP: 30.96 (+0.10), AMPE: 2.89 (+0.20), ANIK: 38.68 (+0.05), CBYL: 7.02 (-0.38)
Xenon off on profit taking
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 11:01AM CST
XENE: 14.25 (-0.66)
Xenon Pharmaceuticals (XENE) Jumps: Stock Surges 16.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 8:11AM CST
Xenon Pharmaceuticals Inc. (XENE) was a big mover last session, as the company saw its shares rise by nearly 17% on the day.
ANIP: 69.79 (+1.24), XENE: 14.25 (-0.66)
Market News: Manitowoc, Xenon Pharmaceuticals, USMD Holdings
at The Street - Mon Dec 29, 3:43PM CST
The stock markets in the United States fluctuated and eventually ended the trading session higher except Dow Jones Industrial Average (DJIA), down by 0.9% today. Sign up for our free daily newsletter ...
XENE: 14.25 (-0.66), USMD: 10.37 (-0.08), MTW: 19.99 (+0.39)
Xenon Pharma continues up move
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 9:25AM CST
XENE: 14.25 (-0.66)
Xenon Pharma ups earnings 44% in Q3
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 7:43AM CST
XENE: 14.25 (-0.66)
